Tumor immunogenicity and responsiveness to cancer vaccine therapy: The state of the art

Taylor H. Schreiber, Luis Raez, Joseph D Rosenblatt, Eckhard R. Podack

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Despite enormous effort, promising pre-clinical data in animal studies and over 900 clinical trials in the United States, no cancer vaccine has ever been approved for clinical use. Over the past decade a great deal of progress has been in both laboratory and clinical studies defining the interactions between developing tumors and the immune system. The results of these studies provide a rationale that may help explain the failure of recent therapeutic cancer vaccines in terms of vaccine principles, in selecting which tumors are the most appropriate to target and instruct the design and implementation of state-of-the-art cancer vaccines.

Original languageEnglish
Pages (from-to)105-112
Number of pages8
JournalSeminars in Immunology
Volume22
Issue number3
DOIs
StatePublished - Jun 1 2010

Fingerprint

Active Immunotherapy
Cancer Vaccines
Neoplasms
Immune System
Vaccines
Clinical Trials
Therapeutics

Keywords

  • Cancer
  • Immunosurveillance
  • Immunotherapy
  • Vaccine(s)

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Tumor immunogenicity and responsiveness to cancer vaccine therapy : The state of the art. / Schreiber, Taylor H.; Raez, Luis; Rosenblatt, Joseph D; Podack, Eckhard R.

In: Seminars in Immunology, Vol. 22, No. 3, 01.06.2010, p. 105-112.

Research output: Contribution to journalArticle

Schreiber, Taylor H. ; Raez, Luis ; Rosenblatt, Joseph D ; Podack, Eckhard R. / Tumor immunogenicity and responsiveness to cancer vaccine therapy : The state of the art. In: Seminars in Immunology. 2010 ; Vol. 22, No. 3. pp. 105-112.
@article{1290eacc805540b7aa64e1c3d3a33004,
title = "Tumor immunogenicity and responsiveness to cancer vaccine therapy: The state of the art",
abstract = "Despite enormous effort, promising pre-clinical data in animal studies and over 900 clinical trials in the United States, no cancer vaccine has ever been approved for clinical use. Over the past decade a great deal of progress has been in both laboratory and clinical studies defining the interactions between developing tumors and the immune system. The results of these studies provide a rationale that may help explain the failure of recent therapeutic cancer vaccines in terms of vaccine principles, in selecting which tumors are the most appropriate to target and instruct the design and implementation of state-of-the-art cancer vaccines.",
keywords = "Cancer, Immunosurveillance, Immunotherapy, Vaccine(s)",
author = "Schreiber, {Taylor H.} and Luis Raez and Rosenblatt, {Joseph D} and Podack, {Eckhard R.}",
year = "2010",
month = "6",
day = "1",
doi = "10.1016/j.smim.2010.02.001",
language = "English",
volume = "22",
pages = "105--112",
journal = "Seminars in Immunology",
issn = "1044-5323",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Tumor immunogenicity and responsiveness to cancer vaccine therapy

T2 - The state of the art

AU - Schreiber, Taylor H.

AU - Raez, Luis

AU - Rosenblatt, Joseph D

AU - Podack, Eckhard R.

PY - 2010/6/1

Y1 - 2010/6/1

N2 - Despite enormous effort, promising pre-clinical data in animal studies and over 900 clinical trials in the United States, no cancer vaccine has ever been approved for clinical use. Over the past decade a great deal of progress has been in both laboratory and clinical studies defining the interactions between developing tumors and the immune system. The results of these studies provide a rationale that may help explain the failure of recent therapeutic cancer vaccines in terms of vaccine principles, in selecting which tumors are the most appropriate to target and instruct the design and implementation of state-of-the-art cancer vaccines.

AB - Despite enormous effort, promising pre-clinical data in animal studies and over 900 clinical trials in the United States, no cancer vaccine has ever been approved for clinical use. Over the past decade a great deal of progress has been in both laboratory and clinical studies defining the interactions between developing tumors and the immune system. The results of these studies provide a rationale that may help explain the failure of recent therapeutic cancer vaccines in terms of vaccine principles, in selecting which tumors are the most appropriate to target and instruct the design and implementation of state-of-the-art cancer vaccines.

KW - Cancer

KW - Immunosurveillance

KW - Immunotherapy

KW - Vaccine(s)

UR - http://www.scopus.com/inward/record.url?scp=77953610923&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953610923&partnerID=8YFLogxK

U2 - 10.1016/j.smim.2010.02.001

DO - 10.1016/j.smim.2010.02.001

M3 - Article

C2 - 20226686

AN - SCOPUS:77953610923

VL - 22

SP - 105

EP - 112

JO - Seminars in Immunology

JF - Seminars in Immunology

SN - 1044-5323

IS - 3

ER -